-
1 week ago | 
drugdiscoverynews.com | Bree Coven Foster
Spatial proteomics is a powerful tool in biomedical research, enabling scientists to study the spatial distribution of proteins within tissues to gain deeper insights into cellular function and disease mechanisms. By mapping protein expression and localization in situ, spatial proteomics can reveal critical information about tumor microenvironments, immune cell interactions, and treatment responses that traditional bulk analyses cannot capture.
-
1 week ago | 
drugdiscoverynews.com | Bree Coven Foster
Pharmaceutical companies are investing in supply chain visibility, ethical sourcing, and proactive strategies to build resilience and protect patient access. CREDIT: iStock.com/Pla2naPharmaceutical companies are investing in supply chain visibility, ethical sourcing, and proactive strategies to build resilience and protect patient access.
-
1 week ago | 
drugdiscoverynews.com | Bree Coven Foster
The pharmaceutical supply chain is under significant pressure, driven by escalating U.S. tariffs and global trade tensions. Recent policy shifts, including a 10 percent universal import tariff and proposed tariffs on foreign made pharmaceuticals, are disrupting sourcing strategies, increasing costs, and threatening the availability of essential medications.
-
1 month ago | 
drugdiscoverynews.com | Bree Coven Foster |Revvity Signals
The pace of innovation in drug discovery is accelerating, driven by advances in genomics, automation, and data science. As research becomes more complex, so do the requirements for the software tools that support it.
-
1 month ago | 
drugdiscoverynews.com | Bree Coven Foster
As microfluidics continue to gain ground as a critical enabler of single-cell research and therapeutic development, companies at the forefront of the field are evolving to meet growing demand for scalable, integrated solutions.
-
1 month ago | 
drugdiscoverynews.com | Bree Coven Foster
Synthetic DNA is increasingly used for gene therapies due to its fast production and improved scalability compared to traditional plasmid-based methods. Credit: iStock.com/ktsimageSynthetic DNA is increasingly used for gene therapies due to its fast production and improved scalability compared to traditional plasmid-based methods.
-
1 month ago | 
drugdiscoverynews.com | Bree Coven Foster
In the world of drug development, securing timely access to fill/finish services can often pose a critical bottleneck, especially for clinical trials requiring small-volume production. Fill/finish refers to the final steps in the production of injectable pharmaceutical drug substances, including the process of filling vials with a drug substance, sealing them, and ensuring they are sterile and ready for use in clinical settings.
-
1 month ago | 
drugdiscoverynews.com | Bree Coven Foster
Duchenne muscular dystrophy (DMD) has long been understood as a disease driven by the absence of dystrophin, a protein essential for maintaining muscle integrity. Most therapeutic efforts have focused on restoring dystrophin through gene therapy, exon-skipping, or other genetic approaches. However, emerging research suggests that dystrophin’s role extends beyond structural support — it also plays a critical part in regulating muscle regeneration.
-
1 month ago | 
drugdiscoverynews.com | Bree Coven Foster
From understanding immune responses to screening new drug candidates, flow cytometry plays a critical role in modern biomedical research. By rapidly analyzing thousands of cells per second, researchers can gather precise, multiparametric data at the single-cell level. Recent innovations in automation and high-throughput screening have further expanded the technology’s potential, making it a powerful tool for drug discovery.
-
Nov 9, 2023 | 
dev.alto-marketing.com | Bree Coven Foster |Naomi Buckland
Every year, around 56,000 women in the UK are diagnosed with breast cancer – about 150 a day [1]. While significant progress has been made in diagnosis, treatment, and survival rates, this disease still claims around 11,500 lives annually. However, there’s promising news on the horizon, particularly for women at an increased risk of breast cancer. Anastrozole, a well-established breast cancer treatment, has now been licensed for a new purpose: prevention [2].
